TELDAZIA
DEAD

Serial Number

98210357

Owner

Alkermes Pharma Ireland Limited

Attorney

Norm J. Rich

Filing Date

Oct 5, 2023

Add to watchlist:

No watchlists yet
View on USPTO

TELDAZIA Trademark

Serial Number: 98210357

TELDAZIA is a trademark filed by Alkermes Pharma Ireland Limited on October 5, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Alkermes Pharma Ireland Limited (87 trademarks)

Connaught House
Dublin 4 , IE

Entity Type: 99

MURAL ONCOLOGY, INC. (8 trademarks)

852 WINTER STREET
WALTHAM, MA 02451

Entity Type: 03

Trademark Details

Filing Date

October 5, 2023

Registration Date

Not Registered

Published for Opposition

September 10, 2024

Goods & Services

Biopharmaceutical active substances, namely, pharmaceutical preparations and substances for the treatment of oncological-related diseases and disorders; Biological preparations for the treatment of cancer; Engineered fusion proteins for medical diagnostic and treatment purposes, namely, engineered fusion proteins created through the use of circular permutation technology for use in the treatment of cancer and cancer-related disorders; Engineered interleukin protein pharmaceutical preparations for use in optimizing patients' immune cellular response to prevent cancer-associated morbidity and mortality; Pharmaceutical preparations, namely, tumor-targeted immunotherapeutic fusion proteins for the treatment of cancer and cancer-related disorders; Cytokine inhibitory pharmaceutical and biological preparations for use in the treatment of oncology-related diseases and disorders; Biological and chemical immunotherapy preparations comprising anti-body-cytokine fusion protein pharmaceutical preparations for use in the medical treatment and prevention of cancer

Providing educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing information in the field of cancer prevention, screening, diagnosis and treatment

Therapeutic proteins for use in the manufacture of pharmaceutical preparations

Research and development of medicines for use in the fields of oncology-related diseases and disorders; Protein engineering for others for use in the development of pharmaceuticals; Protein structure modifications for others for use in the development of pharmaceuticals, namely, conducting pharmaceutical research and development of engineered protein therapeutic pharmaceuticals and biopharmaceuticals for others; Conducting medical and scientific research in the fields of oncology-related diseases and disorders for others; Conducting clinical medical research for others in the field of cancerous diseases and disorders; Clinical research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Scientific research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Providing information and data about medical and scientific research and development in the fields of pharmaceuticals, biopharmaceuticals, clinical trials, therapeutic proteins, and fusion proteins, used to treat cancerous diseases and disorders; Providing websites featuring medical and scientific research information about pharmaceutical and biopharmaceutical drugs and their preparations; Cytokine engineering and cytokine research and development for use in the development of pharmaceuticals, namely, conducting pharmaceutical research, engineering and products development for others in the fields of cancer, immunopharmaceuticals for use in the treatment of cancer and engineered cytokine therapeutic pharmaceuticals and bio-pharmaceuticals for use in the treatment of cancer and cancer-related disorders; Conducting scientific research for others in the field of cytokine biology for use in pharmaceutical research and development; Scientific research and development of immune modulating proteins for others for use in the development of pharmaceuticals; Scientific research and development for others of cytokine based biopharmaceutical treatments for oncology-related diseases and disorders; Conducting protein based therapeutic medical research and pharmaceutical products development for others in the field of pharmaceuticals and biopharmaceuticals for the treatment of cancer and related diseases and disorders; Protein or cytokine based cancer immunotherapy research and development, namely, conducting pharmaceutical research and products development for others in the field of cancer; Providing educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing medical and scientific research information about clinical trials featuring pharmaceutical treatments in the field of oncology

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Dec 8, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Dec 8, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 6, 2025 EXRA
SOU EXTENSION 1 GRANTED
Jan 6, 2025 EX1G
SOU EXTENSION 1 FILED
Jan 6, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 6, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 5, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 10, 2024 NPUB
PUBLISHED FOR OPPOSITION
Sep 10, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 21, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 8, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 11, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 11, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 11, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 11, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 23, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 23, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 23, 2024 TROA
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Feb 28, 2024 ASGN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 24, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 24, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jan 24, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 23, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 13, 2023 NWOS
NEW APPLICATION ENTERED
Oct 9, 2023 NWAP